Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

    September 21, 2023

    Liftoff for the Biotech Launch Pad

    September 20, 2023

    Five things: A biotech IPO, Shannon O’Brien suspension, life sciences philanthropy report

    September 19, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

      September 21, 2023

      Liftoff for the Biotech Launch Pad

      September 20, 2023

      Five things: A biotech IPO, Shannon O’Brien suspension, life sciences philanthropy report

      September 19, 2023

      Machine learning biotech raises $273 million in rare successful late-stage round

      September 15, 2023

      Discover the synergy between biotech, medtech and digital health in Ghent, a European technology capital

      September 14, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»This biotech founder has a new plan to treat Tourette Syndrome, which affects 200,000 Americans each year
    Bio Technology

    This biotech founder has a new plan to treat Tourette Syndrome, which affects 200,000 Americans each year

    yourbiotechBy yourbiotechJanuary 6, 2023Updated:January 6, 2023No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Tourette Syndrome, the nervous system disorder that causes tics, or rapid and repetitive twitches and sounds that are involuntary, can be a debilitating condition.

    While there are no reliable estimates of how common Tourette Syndrome is in adults, the Tourette Association of America estimates that the disease occurs in more than 1 in 160 children and that it is more common in boys than girls. The American Brain Foundation estimates that around 200,000 Americans have the most severe form of the condition.

    Tourette Syndrome currently has no cure and few treatment options. According to a survey of more than 1,100 people with Tourette Syndrome conducted by the Tourette Association of America, many patients report trying several medications to try and control their symptoms but say they don’t feel current drugs do a good enough job at remedying their condition.

    Jeff Aronin, CEO of life sciences accelerator Paragon Biosciences, told Insider that Tourette Syndrome as a condition stood out to him because the disorder can be physically painful for patients but it is also socially challenging. According to the Tourette Association survey, half of the adults with the condition said that tics prevented them from forming meaningful friendships or romantic relationships, and 27% reported attempting suicide in the past 12 months.

    Aronin realized there was an unmet need where he could step in. He told Insider that while most drug developers find a molecule in a lab that could potentially treat a certain illness and then pursue that molecule through clinical trials, he’s taken the opposite approach. Instead, he and his team at Paragon identify an illness that needs more attention and then work backward from there to figure out what kind of drug might work best to treat that illness.

    That’s how in 2018 he came to found Emalex Biosciences, a pharmaceutical startup, to test a new drug for Tourette Syndrome.

    The suffering, the misunderstanding of how serious and significant it is, I think really put it over the top

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleMaxCyte Licences With Catamaran Bio to Advance Its CAR-NK Cell Therapy Programs
    Next Article Biotech Stocks To Watch And Pharma Industry News
    yourbiotech
    • Website

    Related Posts

    Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

    September 21, 2023

    Liftoff for the Biotech Launch Pad

    September 20, 2023

    Five things: A biotech IPO, Shannon O’Brien suspension, life sciences philanthropy report

    September 19, 2023

    Machine learning biotech raises $273 million in rare successful late-stage round

    September 15, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.